Antares Pharma has reacquired the US rights to its needle-free injector technology that were bought exclusively by Bio-Technology General in December 1999 for the administration of growth hormones. The Exton, Pennsylvania company says it will now seek other partners that could achieve a level of success similar to that achieved by Ferring Pharmaceuticals, its partner in Europe.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?